RH
Roche Holding AG
RHHVF · OTC
$442.60 +6.66% (+$27.62)
1M +3.06%
Market Cap CHF 243.6B
P/E Ratio 29.66x
Div. Yield 6.05%
ROE -
Bulios Fair Price
$309.76
30.0% downside
Current Price
$442.6
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RHHVF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
47 /100
Fair P/E 29.66x
EV/EBITDA 16.43x
P/S 3.90x
Growth
16 /100
Declining EPS growth 0.54%
Rev. growth 0.97%
FCF growth 7.45%
Profitability
92 /100
Strong Gross margin 73.90%
Net margin 13.27%
Op. margin 21.50%
Quality
68 /100
Excellent ROIC 13.22%
ROA 8.13%
Asset turnover 0.61x
Debt
65 /100
Moderate Debt/Equity 1.14x
Current ratio 1.48x
Int. coverage 9.41x
Stability
84 /100
Stable Beta 0.35x
Rev. volatility 6.40%
EPS volatility 5.60%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RHHVF
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Thomas Schinecker
Employees
103,249
Headquarters
Basel
Upcoming events
04 FEB
Earnings
Upcoming earnings report